Table 1.

Clinical and laboratory features of the ALL at diagnosis and AML at transformation.

Clinical data	At diagnosis	Follow up	At relapse
Bone marrow blast count	96% lymphoblasts	Less than 3% blast/hematogones	88% myeloblast
Flow cytometry	HLA-DR+, CD7+ (dim), CD19+, CD38+, MPO−, CD13−, CD15−, CD33−, and CD34−	MRD undetectable	MPO+, CD13+ (dim), CD15+, CD33+, CD38+, CD64+, CD 36+, CD19-, CD22−, and CD117−
Cytogenetics	Baseline cytogenetics normal	Not tested	t(15 17) (q21 q22), Inv 16 (p13 q22), and t(8 21) (q22 q22) negative
FISH	FISH for ALL: BCR/ABL: t(9:22) – normal MLL gene rearrangement; t(11q23) – normal E2A gene rearrangement – normal TEL/AML1 ES; t(12;21) – normal	Not tested	17p13 loss positive
Lumbar puncture	Negative	Not tested	Negative